α-synuclein oligomers and clinical implications for parkinson disease

Lorraine V. Kalia, Suneil K. Kalia, Pamela J McLean, Andres M. Lozano, Anthony E. Lang

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

Protein aggregation within the central nervous system has been recognized as a defining feature of neurodegenerative diseases since the early 20th century. Since that time, there has been a growing list of neurodegenerative disorders, including Parkinson disease, which are characterized by inclusions of specific pathogenic proteins. This has led to the long-held dogma that these characteristic protein inclusions, which are composed of large insoluble fibrillar protein aggregates and visible by light microscopy, are responsible for cell death in these diseases. However, the correlation between protein inclusion formation and cytotoxicity is inconsistent, suggesting that another form of the pathogenic proteins may be contributing to neurodegeneration. There is emerging evidence implicating soluble oligomers, smaller protein aggregates not detectable by conventional microscopy, as potential culprits in the pathogenesis of neurodegenerative diseases. The protein α-synuclein is well recognized to contribute to the pathogenesis of Parkinson disease and is the major component of Lewy bodies and Lewy neurites. However, α-synuclein also forms oligomeric species, with certain conformations being toxic to cells. The mechanisms by which these α-synuclein oligomers cause cell death are being actively investigated, as they may provide new strategies for diagnosis and treatment of Parkinson disease and related disorders. Here we review the possible role of α-synuclein oligomers in cell death in Parkinson disease and discuss the potential clinical implications. ANN NEUROL 2013;73:155-169

Original languageEnglish (US)
Pages (from-to)155-169
Number of pages15
JournalAnnals of Neurology
Volume73
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Synucleins
Parkinson Disease
Neurodegenerative Diseases
Proteins
Cell Death
Microscopy
Lewy Bodies
Poisons
Neurites
Cause of Death
Central Nervous System
Light

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

α-synuclein oligomers and clinical implications for parkinson disease. / Kalia, Lorraine V.; Kalia, Suneil K.; McLean, Pamela J; Lozano, Andres M.; Lang, Anthony E.

In: Annals of Neurology, Vol. 73, No. 2, 02.2013, p. 155-169.

Research output: Contribution to journalArticle

Kalia, Lorraine V. ; Kalia, Suneil K. ; McLean, Pamela J ; Lozano, Andres M. ; Lang, Anthony E. / α-synuclein oligomers and clinical implications for parkinson disease. In: Annals of Neurology. 2013 ; Vol. 73, No. 2. pp. 155-169.
@article{2de1dc45be964be189b412eafdaf0236,
title = "α-synuclein oligomers and clinical implications for parkinson disease",
abstract = "Protein aggregation within the central nervous system has been recognized as a defining feature of neurodegenerative diseases since the early 20th century. Since that time, there has been a growing list of neurodegenerative disorders, including Parkinson disease, which are characterized by inclusions of specific pathogenic proteins. This has led to the long-held dogma that these characteristic protein inclusions, which are composed of large insoluble fibrillar protein aggregates and visible by light microscopy, are responsible for cell death in these diseases. However, the correlation between protein inclusion formation and cytotoxicity is inconsistent, suggesting that another form of the pathogenic proteins may be contributing to neurodegeneration. There is emerging evidence implicating soluble oligomers, smaller protein aggregates not detectable by conventional microscopy, as potential culprits in the pathogenesis of neurodegenerative diseases. The protein α-synuclein is well recognized to contribute to the pathogenesis of Parkinson disease and is the major component of Lewy bodies and Lewy neurites. However, α-synuclein also forms oligomeric species, with certain conformations being toxic to cells. The mechanisms by which these α-synuclein oligomers cause cell death are being actively investigated, as they may provide new strategies for diagnosis and treatment of Parkinson disease and related disorders. Here we review the possible role of α-synuclein oligomers in cell death in Parkinson disease and discuss the potential clinical implications. ANN NEUROL 2013;73:155-169",
author = "Kalia, {Lorraine V.} and Kalia, {Suneil K.} and McLean, {Pamela J} and Lozano, {Andres M.} and Lang, {Anthony E.}",
year = "2013",
month = "2",
doi = "10.1002/ana.23746",
language = "English (US)",
volume = "73",
pages = "155--169",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - α-synuclein oligomers and clinical implications for parkinson disease

AU - Kalia, Lorraine V.

AU - Kalia, Suneil K.

AU - McLean, Pamela J

AU - Lozano, Andres M.

AU - Lang, Anthony E.

PY - 2013/2

Y1 - 2013/2

N2 - Protein aggregation within the central nervous system has been recognized as a defining feature of neurodegenerative diseases since the early 20th century. Since that time, there has been a growing list of neurodegenerative disorders, including Parkinson disease, which are characterized by inclusions of specific pathogenic proteins. This has led to the long-held dogma that these characteristic protein inclusions, which are composed of large insoluble fibrillar protein aggregates and visible by light microscopy, are responsible for cell death in these diseases. However, the correlation between protein inclusion formation and cytotoxicity is inconsistent, suggesting that another form of the pathogenic proteins may be contributing to neurodegeneration. There is emerging evidence implicating soluble oligomers, smaller protein aggregates not detectable by conventional microscopy, as potential culprits in the pathogenesis of neurodegenerative diseases. The protein α-synuclein is well recognized to contribute to the pathogenesis of Parkinson disease and is the major component of Lewy bodies and Lewy neurites. However, α-synuclein also forms oligomeric species, with certain conformations being toxic to cells. The mechanisms by which these α-synuclein oligomers cause cell death are being actively investigated, as they may provide new strategies for diagnosis and treatment of Parkinson disease and related disorders. Here we review the possible role of α-synuclein oligomers in cell death in Parkinson disease and discuss the potential clinical implications. ANN NEUROL 2013;73:155-169

AB - Protein aggregation within the central nervous system has been recognized as a defining feature of neurodegenerative diseases since the early 20th century. Since that time, there has been a growing list of neurodegenerative disorders, including Parkinson disease, which are characterized by inclusions of specific pathogenic proteins. This has led to the long-held dogma that these characteristic protein inclusions, which are composed of large insoluble fibrillar protein aggregates and visible by light microscopy, are responsible for cell death in these diseases. However, the correlation between protein inclusion formation and cytotoxicity is inconsistent, suggesting that another form of the pathogenic proteins may be contributing to neurodegeneration. There is emerging evidence implicating soluble oligomers, smaller protein aggregates not detectable by conventional microscopy, as potential culprits in the pathogenesis of neurodegenerative diseases. The protein α-synuclein is well recognized to contribute to the pathogenesis of Parkinson disease and is the major component of Lewy bodies and Lewy neurites. However, α-synuclein also forms oligomeric species, with certain conformations being toxic to cells. The mechanisms by which these α-synuclein oligomers cause cell death are being actively investigated, as they may provide new strategies for diagnosis and treatment of Parkinson disease and related disorders. Here we review the possible role of α-synuclein oligomers in cell death in Parkinson disease and discuss the potential clinical implications. ANN NEUROL 2013;73:155-169

UR - http://www.scopus.com/inward/record.url?scp=84875415994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875415994&partnerID=8YFLogxK

U2 - 10.1002/ana.23746

DO - 10.1002/ana.23746

M3 - Article

C2 - 23225525

AN - SCOPUS:84875415994

VL - 73

SP - 155

EP - 169

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -